Skip to main content
Top
Published in: Diabetologia 2/2010

Open Access 01-02-2010 | Article

Progression to microalbuminuria in type 1 diabetes: development and validation of a prediction rule

Authors: Y. Vergouwe, S. S. Soedamah-Muthu, J. Zgibor, N. Chaturvedi, C. Forsblom, J. K. Snell-Bergeon, D. M. Maahs, P.-H. Groop, M. Rewers, T. J. Orchard, J. H. Fuller, K. G. M. Moons

Published in: Diabetologia | Issue 2/2010

Login to get access

Abstract

Aims/hypothesis

Microalbuminuria is common in type 1 diabetes and is associated with an increased risk of renal and cardiovascular disease. We aimed to develop and validate a clinical prediction rule that estimates the absolute risk of microalbuminuria.

Methods

Data from the European Diabetes Prospective Complications Study (n = 1115) were used to develop the prediction rule (development set). Multivariable logistic regression analysis was used to assess the association between potential predictors and progression to microalbuminuria within 7 years. The performance of the prediction rule was assessed with calibration and discrimination (concordance statistic [c-statistic]) measures. The rule was validated in three other diabetes studies (Pittsburgh Epidemiology of Diabetes Complications [EDC] study, Finnish Diabetic Nephropathy [FinnDiane] study and Coronary Artery Calcification in Type 1 Diabetes [CACTI] study).

Results

Of patients in the development set, 13% were microalbuminuric after 7 years. Glycosylated haemoglobin, AER, WHR, BMI and ever smoking were found to be the most important predictors. A high-risk group (n = 87 [8%]) was identified with a risk of progression to microalbuminuria of 32%. Predictions showed reasonable discriminative ability, with c-statistic of 0.71. The rule showed good calibration and discrimination in EDC, FinnDiane and CACTI (c-statistic 0.71, 0.79 and 0.79, respectively).

Conclusions/interpretation

We developed and validated a clinical prediction rule that uses relatively easily obtainable patient characteristics to predict microalbuminuria in patients with type 1 diabetes. This rule can help clinicians to decide on more frequent check-ups for patients at high risk of microalbuminuria in order to prevent long-term chronic complications.
Appendix
Available only for authorised users
Literature
1.
go back to reference Orchard TJ, Dorman JS, Maser RE et al (1990) Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 39:1116–1124CrossRefPubMed Orchard TJ, Dorman JS, Maser RE et al (1990) Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 39:1116–1124CrossRefPubMed
2.
go back to reference Hovind P, Tarnow L, Rossing P et al (2004) Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 328:1105CrossRefPubMed Hovind P, Tarnow L, Rossing P et al (2004) Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 328:1105CrossRefPubMed
3.
go back to reference Coonrod BA, Ellis D, Becker DJ et al (1993) Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes care 16:1376–1383CrossRefPubMed Coonrod BA, Ellis D, Becker DJ et al (1993) Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes care 16:1376–1383CrossRefPubMed
4.
go back to reference Group MCS (1999) Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven-year prospective study. Diabet Med 16:918–925CrossRef Group MCS (1999) Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven-year prospective study. Diabet Med 16:918–925CrossRef
5.
go back to reference Rossing P, Hougaard P, Parving HH (2002) Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes care 25:859–864CrossRefPubMed Rossing P, Hougaard P, Parving HH (2002) Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes care 25:859–864CrossRefPubMed
6.
go back to reference Mogensen CE, Christensen CK (1984) Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311:89–93PubMedCrossRef Mogensen CE, Christensen CK (1984) Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311:89–93PubMedCrossRef
7.
go back to reference Almdal T, Norgaard K, Feldt-Rasmussen B, Deckert T (1994) The predictive value of microalbuminuria in IDDM. A five-year follow-up study. Diabetes care 17:120–125CrossRefPubMed Almdal T, Norgaard K, Feldt-Rasmussen B, Deckert T (1994) The predictive value of microalbuminuria in IDDM. A five-year follow-up study. Diabetes care 17:120–125CrossRefPubMed
8.
go back to reference Krolewski AS, Kosinski EJ, Warram JH et al (1987) Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 59:750–755CrossRefPubMed Krolewski AS, Kosinski EJ, Warram JH et al (1987) Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 59:750–755CrossRefPubMed
9.
go back to reference Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387CrossRefPubMed Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387CrossRefPubMed
10.
go back to reference Steyerberg EW, Eijkemans MJC, Harrell FE Jr, Habbema JDF (2000) Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med 19:1059–1079CrossRefPubMed Steyerberg EW, Eijkemans MJC, Harrell FE Jr, Habbema JDF (2000) Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med 19:1059–1079CrossRefPubMed
11.
go back to reference Group EICS (1994) Microvascular and acute complications in IDDM patients. Diabetologia 37:278–285CrossRef Group EICS (1994) Microvascular and acute complications in IDDM patients. Diabetologia 37:278–285CrossRef
12.
go back to reference Thorn LM, Forsblom C, Fagerudd J et al (2005) Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 28:2019–2024CrossRefPubMed Thorn LM, Forsblom C, Fagerudd J et al (2005) Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 28:2019–2024CrossRefPubMed
13.
go back to reference Dabelea D, Kinney G, Snell-Bergeon JK et al (2003) Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes 52:2833–2839CrossRefPubMed Dabelea D, Kinney G, Snell-Bergeon JK et al (2003) Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes 52:2833–2839CrossRefPubMed
14.
go back to reference Kearney EM, Mount JN, Watts GF, Slavin BM, Kind PR (1987) Simple immunoturbidimetric method for determining urinary albumin at low concentrations using Cobas-Bio centrifugal analyser. J Clin Pathol 40:465–468CrossRefPubMed Kearney EM, Mount JN, Watts GF, Slavin BM, Kind PR (1987) Simple immunoturbidimetric method for determining urinary albumin at low concentrations using Cobas-Bio centrifugal analyser. J Clin Pathol 40:465–468CrossRefPubMed
15.
go back to reference Ellis D, Buffone GJ (1977) New approach to evaluation of proteinuric states. Clin Chem 23:666–670PubMed Ellis D, Buffone GJ (1977) New approach to evaluation of proteinuric states. Clin Chem 23:666–670PubMed
16.
go back to reference Chaturvedi N, Sjoelie AK, Porta M et al (2001) Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 24:284–289CrossRefPubMed Chaturvedi N, Sjoelie AK, Porta M et al (2001) Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 24:284–289CrossRefPubMed
17.
go back to reference Atkinson AC (1980) A note on the generalized information criterion for choice of a model. Biometrika 67:413–418CrossRef Atkinson AC (1980) A note on the generalized information criterion for choice of a model. Biometrika 67:413–418CrossRef
18.
go back to reference Efron B, Tibshirani RJ (1993) An introduction to the bootstrap. Chapman and Hall, London Efron B, Tibshirani RJ (1993) An introduction to the bootstrap. Chapman and Hall, London
19.
go back to reference Steyerberg EW, Eijkemans MJ, Habbema JD (1999) Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis. J Clin Epidemiol 52:935–942CrossRefPubMed Steyerberg EW, Eijkemans MJ, Habbema JD (1999) Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis. J Clin Epidemiol 52:935–942CrossRefPubMed
20.
go back to reference Royston P, Altman DG, Sauerbrei W (2006) Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 25:127–141CrossRefPubMed Royston P, Altman DG, Sauerbrei W (2006) Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 25:127–141CrossRefPubMed
21.
go back to reference Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247:2543–2546CrossRefPubMed Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247:2543–2546CrossRefPubMed
22.
go back to reference Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH (2001) Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 60:219–227CrossRefPubMed Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH (2001) Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 60:219–227CrossRefPubMed
23.
go back to reference Kannel WB, Cupples LA, Ramaswami R, Stokes J 3rd, Kreger BE, Higgins M (1991) Regional obesity and risk of cardiovascular disease; the Framingham Study. J Clin Epidemiol 44:183–190CrossRefPubMed Kannel WB, Cupples LA, Ramaswami R, Stokes J 3rd, Kreger BE, Higgins M (1991) Regional obesity and risk of cardiovascular disease; the Framingham Study. J Clin Epidemiol 44:183–190CrossRefPubMed
24.
go back to reference Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ (2000) Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49:626–632CrossRefPubMed Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ (2000) Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49:626–632CrossRefPubMed
25.
go back to reference Group TES (1997) Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349:1787–1792CrossRef Group TES (1997) Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349:1787–1792CrossRef
26.
go back to reference Douglas K, O'Malley PG, Jackson JL (2006) Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 145:117–124PubMed Douglas K, O'Malley PG, Jackson JL (2006) Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 145:117–124PubMed
27.
go back to reference Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N (2004) Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia 47:1020–1028CrossRefPubMed Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N (2004) Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia 47:1020–1028CrossRefPubMed
28.
go back to reference Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS (2003) Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348:2285–2293CrossRefPubMed Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS (2003) Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348:2285–2293CrossRefPubMed
Metadata
Title
Progression to microalbuminuria in type 1 diabetes: development and validation of a prediction rule
Authors
Y. Vergouwe
S. S. Soedamah-Muthu
J. Zgibor
N. Chaturvedi
C. Forsblom
J. K. Snell-Bergeon
D. M. Maahs
P.-H. Groop
M. Rewers
T. J. Orchard
J. H. Fuller
K. G. M. Moons
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 2/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1585-3

Other articles of this Issue 2/2010

Diabetologia 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.